Beta Bionics, Inc. Common Stock BBNX
$22.18
+15.34%
at last close
Analyst Consensus
- Consensus Rating
- Moderate Buy (7 Buy · 4 Hold · 0 Sell)
- Average Price Target
- $23.60
- Implied Upside
- +6.4%
- Price Target Range
- $16.00 – $40.00
- Analysts (12 mo)
- 11
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-09-15 | B of A SecuritiesTravis Steed |
Maintains | Neutral | $18 → $20 |
| 2026-09-15 | Truist SecuritiesRichard Newitter |
Reiterates | Buy | $22 → $23 |
| 2026-09-15 | BairdJeff Johnson |
Maintains | Neutral | $14 → $16 |
| 2026-09-14 | Leerink PartnersMike Kratky |
Maintains | Outperform | $24 → $27 |
| 2026-08-21 | William BlairSteven Lichtman |
Initiates coverage on | Market perform | — |
| 2026-07-28 | UBSPatrick Wood |
Assumes | Buy | $22 |
| 2026-07-15 | Goldman SachsDavid Roman |
Maintains | Buy | $17 → $19 |
| 2026-07-13 | Truist SecuritiesRichard Newitter |
Maintains | Buy | $18 → $22 |
| 2026-05-27 | Goldman SachsDavid Roman |
Maintains | Buy | $19 → $17 |
| 2026-05-18 | B of A SecuritiesTravis Steed |
Maintains | Neutral | $23 → $11 |
| 2026-04-22 | Leerink PartnersMike Kratky |
Maintains | Outperform | $25 → $24 |
| 2026-04-22 | StifelJonathan Block |
Maintains | Buy | $22 → $20 |
| 2026-04-15 | Truist SecuritiesRichard Newitter |
Maintains | Buy | $25 → $18 |
| 2026-04-09 | Goldman SachsDavid Roman |
Maintains | Buy | $23 → $20 |
| 2026-02-18 | StifelJonathan Block |
Maintains | Buy | $25 → $22 |
| 2026-02-18 | BairdJeff Johnson |
Maintains | Neutral | $28 → $14 |
| 2026-02-04 | StifelJonathan Block |
Maintains | Buy | $31 → $25 |
| 2026-02-02 | Truist SecuritiesRichard Newitter |
Maintains | Buy | $37 → $25 |
| 2026-01-27 | TD CowenMathew Blackman |
Initiates coverage on | Hold | $17 |
| 2026-01-09 | Lake StreetFrank Takkinen |
Maintains | Buy | $35 → $40 |
| 2026-01-05 | B of A SecuritiesTravis Steed |
Maintains | Buy | $30 → $33 |
| 2025-12-18 | Truist SecuritiesRichard Newitter |
Maintains | Buy | $32 → $37 |
| 2025-10-29 | Goldman SachsDavid Roman |
Maintains | Buy | $26 → $33 |
| 2025-10-29 | StifelJonathan Block |
Reiterates | Buy | $26 → $31 |
| 2025-10-29 | Truist SecuritiesRichard Newitter |
Reiterates | Buy | $28 → $32 |
| 2025-10-29 | Piper SandlerMatt O'Brien |
Reiterates | Overweight | $26 → $32 |
| 2025-10-21 | StifelJonathan Block |
Reinstates | Buy | $26 |
| 2025-10-01 | Goldman SachsDavid Roman |
Upgrades | Neutral → Buy | $18 → $26 |
| 2025-09-22 | Truist SecuritiesRichard Newitter |
Maintains | Buy | $21 → $28 |
| 2025-07-30 | Truist SecuritiesRichard Newitter |
Maintains | Buy | $18 → $21 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $22.18
- Market Cap
- $997.87 million
- 52-Week Range
- $8.80 – $32.71
- Average Volume
- 1.27 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.